Masimo Corporation

Masimo Corporation

MASIยทNASDAQ

$178.78

+0.047%
HealthcareMedical - Devices

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.

At a Glance

Live Snapshot
Market Cap$9.36B
EPS-2.8300
P/E Ratio-63.17
Earnings Date08/04/2026
17.76%
Return on Invested Capital
-238%
3Y+198.0%
5Y+13.0%
10Y-66.0%
-21.01%
Return on Equity
-28%
3Y-296.0%
5Y-223.0%
10Y-139.0%
-8.92%
Return on Assets
-23%
3Y-300.0%
5Y-164.0%
10Y-124.0%
Masimo Corporation

Masimo Corporation Management Team

MASI ยท NASDAQ
DS

Dr. Steven J. Barker

Chairman of Scientific Advisory Board & Chief Science Officer

Compensation

$139,555

Born 1945(Age 81)
MC

Ms. Catherine M. Szyman

Chief Executive Officer & Director

Born 1967(Age 59)
female
MM

Mr. Micah Young CPA

Chief Financial Officer

Compensation

$1,473,831

Born 1979(Age 47)
male
ME

Ms. Elisabeth A. Hellmann

Chief Human Resources Officer

Born 1969(Age 57)
female
MT

Mr. Tim Benner

Chief Marketing & Strategy Officer

male
MB

Mr. Bilal Muhsin

Chief Operating Officer

Compensation

$1,535,895

Born 1982(Age 44)
male
MB

Mr. Blair Tripodi

Chief Operating Officer of Consumer Division

Compensation

$881,703

Born 1974(Age 52)
male
MO

Mr. Omar Ahmed

Chief Technology & Innovation Officer

male
MM

Mr. Micah Young CPA

Executive Vice President & Chief Financial Officer

Compensation

$1,473,831

Born 1980(Age 46)
male
MY

Mr. Yongsam Lee

Executive Vice President & Chief Information Officer

Compensation

$1,100,540

Born 1965(Age 61)
male
MA

Mr. Anand Sampath

Executive Vice President of Operations

Compensation

$774,840

Born 1966(Age 60)
male
MA

Mr. Anand Sampath

Executive Vice President of Operations & Clinical Research

Compensation

$774,840

Born 1966(Age 60)
male
masi

Masimo Corporation Insider Positioning

MASI ยท NASDAQ

During the last 12 months, insiders have purchased $468K and sold $1.63M worth of MASI shares, resulting in $1.16M of net selling activity.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

0

0.00

Sold

11.9K

1.63M

Net Activity

-1.6M

-$1.63M

6-9 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

9-12 Months

Bought

3.2K

468.50K

Sold

0

0.00

Net Activity

+468K

+$468K

Top Buyers

1
JWR

Jellison William R

Director

3.0K sharesโ€ข1 transactions

$438K

2
BM

Brennan Michelle

Director, Other: Chairman Of The Board

200 sharesโ€ข2 transactions

$31K

Top Sellers

1
SA

Sampath Anand

Officer: Evp, Ops & Clinical Research

11.9K sharesโ€ข1 transactions

$1.63M

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $1.16M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.29:1

Weak buy/sell ratio. Selling significantly exceeds buyingโ€”monitor for potential fundamental concerns.

Insider Participation

Moderate Buying

2 insider buyers vs. 1 sellers. More insiders buying than selling indicates positive sentiment.

SEC Filings

MASI - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2025

N/A

March 26, 2025
April 29, 2025
2025
DEF 14A

DEF 14A 2022

N/A

April 05, 2022
January 01, 2022
2022
DEF 14A

DEF 14A 2021

N/A

April 15, 2021
January 02, 2021
2021
DEF 14A

DEF 14A 2019

N/A

April 16, 2020
December 28, 2019
2019
DEF 14A

DEF 14A 2018

N/A

April 12, 2019
December 29, 2018
2018
DEF 14A

DEF 14A 2017

N/A

April 20, 2018
December 30, 2017
2017
DEF 14A

DEF 14A 2016

N/A

April 12, 2017
December 31, 2016
2016
DEF 14A

DEF 14A 2016

N/A

March 16, 2016
January 02, 2016
2016
DEF 14A

DEF 14A 2015

N/A

May 04, 2015
January 03, 2015
2015
DEF 14A

DEF 14A 2014

N/A

April 28, 2014
June 05, 2014
2014
Showing 1 to 10 of 16 filings